Navigation Links
Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
Date:7/30/2008

LONDON, July 30 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a leading European RNAi focused biotechnology company, today announces that its partner, Quark Pharmaceuticals Inc. ("Quark") together with Pfizer, has commenced a Phase II clinical trial with RTP-801i-14 (PF-4523655), a small interfering RNA (siRNA) therapeutic product based on Silence's AtuRNAi technology. Its initiation triggers a $1.9 million milestone payment to Silence from Quark.

The study is designed to evaluate the effectiveness of the candidate in improving visual acuity compared to laser treatment in patients with diabetic macular oedema. The Phase II study is being funded and is conducted by Pfizer Inc. in collaboration with Quark. Pfizer in-licensed RTP-801i-14 from Quark in a deal announced in 2006 for the treatment of age-related macular degeneration (AMD) and other ophthalmologic and non-ophthalmologic indications.

Diabetic macular oedema results in the macula swelling and surrounding blood vessels dilating to compensate for this. The dilated vessels are generally leaky, resulting in fluid build-up in the macula, which in turn causes the macula to swell and cease to function. Diabetic macular oedema is the most common cause of visual impairment in patients with non-proliferative retinopathy. Approximately 14% of people with diabetes have diabetic macular oedema with prevalence increasing to 29% for people with diabetes who use insulin for more than 20 years.

In December 2004 Quark and Silence Therapeutics AG signed a Collaboration Agreement on the development of siRNA molecules for the gene target RTP-801, which resulted in RTP801i-14, a 19 base pairs long blunt-ended AtuRNAi (siRNA) molecule and also provided Quark with a license to AtuRNAi technology. In addition a second agreement (Option and License Agreement) was signed in April 2005, and expanded in 2007, to provide Quark with options for non-exclusive licenses to develop additional molecules agains
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
2. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
3. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
4. Silence Therapeutics Announces Board Changes
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2009)...RNewswire-FirstCall/ -- Sangamo BioSciences, Inc. ...rch milestone has been achieved in its Research an...-owned member of the Roche Group, for the generati...armaceutical protein production purposes using San... nuclease (ZFN) technology. Genentech scientists d...
(Date:6/26/2009)...d OSAKA, Japan, June 27, 2009 Take... announced that Takeda Global Research & Devel...(U.S.) subsidiary received on June 26 (U.S. time) ...Drug Administration (FDA) regarding the Company,s ...tive dipeptidyl peptidase IV (DPP-4) inhibitor und...
(Date:6/26/2009)...nd New Genetic Mutations Acting Together-- , , ...ore pieces in the complex autism inheritance puzzl... team including geneticists from The Children,s Ho...vania School of Medicine and several collaboratin... genetic regions where rare copy number variations...
(Date:6/25/2009)...e-USNewswire/ -- As of mid-2009, The Michael J. Fo...funded over $1 million in high-risk, high-reward a...hrough its groundbreaking Rapid Response Innovati... safety and efficacy of an FDA-approved drug for k...on of a tenuous link between PD and certain strain...
Breaking Medicine Technology:Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 3Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes 2More Gene Mutations Linked to Autism Risk 2More Gene Mutations Linked to Autism Risk 3More Gene Mutations Linked to Autism Risk 4MJFF's Rapid Response Innovation Awards Hit Mid-2009 With Over $1 Million Funded in High-Risk/High-Reward Approaches to Parkinson's Disease 2MJFF's Rapid Response Innovation Awards Hit Mid-2009 With Over $1 Million Funded in High-Risk/High-Reward Approaches to Parkinson's Disease 32007 hurricane forecasts took blow from winds and Saharan dry dusty air 4510 12007 hurricane forecasts took blow from winds and Saharan dry dusty air 4510 22007 hurricane forecasts took blow from winds and Saharan dry dusty air 4510 3The Scientific Business of Thomson Reuters Publishes Three Pharma Matters Reports Covering the First Quarter of 2008 25516 1The Scientific Business of Thomson Reuters Publishes Three Pharma Matters Reports Covering the First Quarter of 2008 25516 2The Scientific Business of Thomson Reuters Publishes Three Pharma Matters Reports Covering the First Quarter of 2008 25516 3Emerging Growth Equities Ltd Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an 2418 00 Price Target 7204 1Emerging Growth Equities Ltd Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an 2418 00 Price Target 7204 2Older Patients Less Likely to Be Taken to Trauma Centers 25508 1Older Patients Less Likely to Be Taken to Trauma Centers 25508 2Older Patients Less Likely to Be Taken to Trauma Centers 25508 3
..., 2007 - According to,The Waismann Method 2006 Opi...ents seeking treatment for opiate dependency have ... OxyContin, Percocet,and Fentanyl were among the d... who reported a dependency said they suffered from...ed addiction,specialist for the Waismann Method., ...
...herapies to Prevent,and Reverse Atherosclerotic He...ewswire/ -- KineMed, Inc.,a pathway-based drug di...he first method for measuring the efflux of choles...known as reverse cholesterol,transport (RCT). RCT ...terol can be removed from tissues and has therefor...
Other Medicine Technology:Waismann Method Survey Reveals 65 Percent of Women Seeking Opiate,Dependency Treatment Are Mothers 2KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 2KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 3
(Date:7/3/2009)...Upstate HomeCare, a home medical services provider...espiratory and DME services, is expanding. Two new...ializes in home infusion therapy and one in oral m.... , Clinton, NY (PRWEB) J... services provider specializing in infusion, speci...
(Date:7/2/2009)...swire-USNewswire/ -- Recent news reports have high...d ensuring that physicians meet high standards in ...erican Board of Medical Specialties (ABMS), which ...eir efforts to develop and implement educational a...ertification of physician specialists. Certificat...
(Date:7/2/2009)... businesses honored in Washington, D.C. , , AR... Texas Health Resources has received the Best Em...ional Business Group on Health. , , (Logo: h...3LOGO ) , , The award recognizes the nation,...t promote a healthy workplace and for helping empl...
(Date:7/2/2009)...own one set of neurons, another set wakes up: stud... -- New information about brain circuit activity m... aid Ambien (zolpidem) walk, eat, talk on the phon...out remembering it the next morning. , The drug... patients into a conscious state. , In experime...
Breaking Medicine News(10 mins):Health News:Upstate HomeCare Expands, Adds Pharmacies 2Health News:Upstate HomeCare Expands, Adds Pharmacies 3Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 2Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 3Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 4Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 2Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 3Health News:Odd Behaviors on Ambien Linked to Brain Circuitry 2
...sician gave us the magic figure of 98.6 degrees. T... over a million armpit temperatures for 25,000 pat...rchers and appears in the April issue of the Harva...normal temperature for adults is found to be 98.2 ...
...lages in western India have tested positive for bi...ts wings// in many more regions, even beyond the a...ing to, state animal husbandry commissioner Bijay ...ogether again to put to sleep some 300,000 chicken...
...ough in the diagnosis of breast cancer –a device t... presence of breast cancer. The device developed ...witchable surface technology. It attracts cells th...r into tiny oil and water-filled pockets, reported...
...006 will be held in Toronto, Canada, June 2-6 2006...ts will present// plenary lectures. Professor Rene...visors and Chairman, IOF World Congress on Osteopo...akers were selected for their ability to present t...
Other Medicine News:
...ted DNA and RNA from agarose gels to hybridization...peed and efficiency of transfer by allowing high p...d system allowing electrophoresis, gel treatment, ...29 hours required for conventional methods ,Positi...
...ted DNA and RNA from agarose gels to hybridization...peed and efficiency of transfer by allowing high p...d system allowing electrophoresis, gel treatment, ...29 hours required for conventional methods ,Positi...
Trans-Blot Plus Gel/Cassette Assembly Tray
PosiBlot 30-30 Masks
Medicine Products: